CG Labz
Peptide Library / Metabolic / Weight Management

Survodutide

GLP-1/Glucagon Dual Agonist

Survodutide Research Protocol

Complete Research Guide 4 min read1 peer-reviewed references

Quickstart Overview

Survodutide (BI 456906) is a GLP-1 and glucagon receptor dual agonist investigated for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It combines appetite suppression with glucagon-driven hepatic fat reduction.

Reconstitution
Add 2.0 mL bacteriostatic water to a 10 mg vial → 5 mg/mL
Measuring Reference
At 5 mg/mL: 1 mg = 0.2 mL = 20 units
Frequency
Once weekly
Route (studies)
Subcutaneous
Class
GLP-1 / glucagon dual agonist
Focus
Obesity and MASH

Scientific Data

Molecular Formula
—
Molecular Weight
—
Sequence
BI 456906
Sequence Length
2
CAS
Research compound
Peptide Family
Dual incretin
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.200 mL
Syringe Units
20.0 U
Doses / Vial
10

Units assume a U-100 insulin syringe (100 units = 1 mL). Of particular research interest for liver (MASH) endpoints.

Frequency: Once weekly

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 24-week protocol at approximately 1000 mcg per day.

Peptide (10 mg vials)
Estimate vials from total mass: 1000 mcg/day × 168 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model GLP-1 + glucagon effects on weight and liver fat.
Schedule
Weekly, titrated.
Dose Range
Per titration schedule.

Dosing Protocol

Weeks 1–4
Low starting dose weekly
Titration
Step up every 2–4 weeks
Maintenance
Target dose per tolerability
Frequency
Once weekly
Timing
Same day weekly
Route
Subcutaneous

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Monitor resting heart rate.
  • Shares the incretin boxed-warning class.
  • Titrate gradually.

How This Works

Survodutide co-activates GLP-1 receptors (satiety, insulinotropic, delayed gastric emptying) and glucagon receptors (hepatic lipid oxidation and energy expenditure). The glucagon component is of particular interest for liver-directed effects, and in a Phase 2 MASH trial a majority of participants achieved histological improvement. Once-weekly dosing is enabled by albumin binding.

Potential Benefits & Side Effects

Reported in research
  • Dose-dependent weight reduction
  • Histological improvement in MASH/fibrosis (Phase 2)
  • Reduced hepatic fat fraction
  • Improved metabolic markers
Possible considerations
  • Nausea, vomiting and GI effects (dose-dependent)
  • Transient heart-rate increase
  • Injection-site reactions
  • Investigational — long-term data limited

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] New England Journal of Medicine
    Sanyal A.J. et al. Survodutide in MASH with fibrosis.
    View Source